Table 1 Baseline and treatment characteristics
From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases
Characteristic | N (%) or median with range | Â | Â | |||
|---|---|---|---|---|---|---|
90Y-resin | 90Y-glass | 166Ho | No extrahepatic disease | Extrahepatic disease at baseline | Total | |
N | 46 (51) | 20 (22) | 24 (27) | 48 (53) | 42 (47) | 90 (100) |
Age (years) | 65 (35–84) | 67 (45–78) | 66 (40–84) | 66 (34–84) | 66 (40–84) | 66 (35–84) |
Gender | Â | Â | Â | Â | Â | Â |
 Male | 33 (72) | 15 (75) | 17 (63) | 34 (71) | 31 (74) | 65 (72) |
 Female | 13 (28) | 5 (25) | 7 (37) | 14 (29) | 11 (26) | 25 (28) |
WHO performance status | Â | Â | Â | Â | Â | Â |
 0 | 24 (52) | 15 (75) | 19 (79) | 29 (60) | 29 (69) | 58 (64) |
 1 | 19 (41) | 5 (25) | 5 (21) | 18 (38) | 11 (26) | 29 (32) |
 2 | 3 (7) | 0 (0) | 0 (0) | 1 (2) | 2 (5) | 3 (4) |
Previous chemotherapy lines | Â | Â | Â | Â | Â | Â |
 0 | 1 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 1 (1) |
 1 | 13 (28) | 9 (45) | 11 (46) | 18 (38) | 15 (36) | 33 (37) |
 2 | 21 (46) | 8 (40) | 11 (46) | 21 (44) | 9 (21) | 40 (44) |
 3 | 11 (24) | 3 (15) | 2 (8) | 8 (17) | 8 (19) | 16 (18) |
Bevacizumab | 29 (63) | 13 (65) | 13 (54) | 32 (67) | 23 (55) | 55 (61) |
Capecitabine | 42 (91) | 18 (90) | 20 (83) | 41 (85) | 39 (93) | 80 (89) |
Cetuximab | 2 (4) | 0 (0) | 1 (4) | 1 (2) | 2 (5) | 3 (4) |
Cisplatin | 1 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 1 (1) |
Erlotinib | 0 (0) | 0 (0) | 1 (4) | 0 (0) | 1 (2) | 1 (1) |
Irinotecan | 26 (57) | 9 (45) | 10 (42) | 23 (48) | 22 (52) | 45 (50) |
Oxaliplatin | 40 (87) | 17 (85) | 23 (96) | 41 (85) | 39 (93) | 80 (89) |
Paclitaxel | 0 (0) | 0 (0) | 1 (4) | 0 (0) | 1 (1) | 1 (1) |
Panitumumab | 8 (17) | 4 (20) | 3 (13) | 9 (19) | 6 (14) | 15 (17) |
5-FU | 7 (15) | 3 (15) | 5 (21) | 7 (15) | 8 (19) | 15 (17) |
Previous locoregional treatment | Â | Â | Â | Â | Â | Â |
 Yes | 17 (37) | 7 (35) | 6 (25) | 17 (35) | 13 (31) | 30 (33) |
 No | 29 (63) | 13 (65) | 18 (75) | 31 (65) | 29 (69) | 60 (67) |
Metastasis pattern | Â | Â | Â | Â | Â | Â |
 Synchronous | 31 (67) | 15 (75) | 15 (63) | 27 (56) | 34 (81) | 61 (68) |
 Metachronous | 15 (33) | 5 (25) | 9 (37) | 21 (44) | 8 (19) | 29 (32) |
Time since diagnosis (months) | 25 (3–97) | 24 (11–110) | 26 (6–92) | 26 (3–110) | 21 (5–92) | 25 (3–110) |
Time since diagnosis of metastatic disease (months) | 17 (3–72) | 23 (2–50) | 18 (2–92) | 17 (2–54) | 21 (5–92) | 19 (2–92) |
KRAS status | Â | Â | Â | Â | Â | Â |
 Wild-type | 16 (35) | 8 (40) | 9 (37) | 21 (44) | 12 (29) | 33 (37) |
 Mutation | 11 (24) | 3 (15) | 6 (26) | 7 (15) | 13 (31) | 20 (22) |
 Unknown | 19 (41) | 9 (45) | 9 (37) | 10 (21) | 17 (40) | 37 (41) |
CEA level | 72 (3–2700) | 68 (3–640) | 100 (2–6000) | 61 (2–2700) | 115 (3–6000) | 88 (2–6000) |
 Unknown | 12 (26) | 4 (20) | 1 (4) | 7 (15) | 10 (24) | 17 (19) |
Primary tumor in situ | Â | Â | Â | Â | Â | Â |
 Yes | 1 (2) | 4 (20) | 2 (8) | 2 (4) | 5 (12) | 7 (8) |
 No | 45 (98) | 16 (80) | 22 (92) | 46 (96) | 37 (88) | 83 (92) |
Extrahepatic disease (all metastases) | Â | Â | Â | Â | Â | Â |
 None | 27 (59) | 9 (45) | 10 (42) | 48 (100) | 0 (0) | 48 (53) |
 Lymph node metastases | 12 (26) | 8 (40) | 7 (29) | - | 25 (60) | 25 (28) |
 Lung metastases | 8 (17) | 2 (10) | 7 (29) | - | 17 (40) | 17 (19) |
 Abdominal wall metastases | 1 (2) | 0 (0) | 0 (0) | - | 1 (2) | 1 (1) |
 Spleen metastases | 0 (0) | 0 (0) | 2 (8) | - | 1 (2) | 1 (1) |
 Adrenal gland metastases | 0 (0) | 2 (10) | 0 (0) | - | 2 (5) | 2 (2) |
 Peritoneal metastases | 1 (2) | 0 (0) | 2 (8) | - | 3 (7) | 3 (3) |
Type of radioembolization | Â | Â | Â | Â | Â | Â |
 Whole-liver | 41 (89) | 12 (60) | 20 (83) | 38 (79) | 35 (83) | 73 (81) |
 Lobar | 5 (11) | 8 (40) | 4 (17) | 10 (21) | 7 (17) | 17 (19) |
Injected activity (MBq) | 1526 (636–2320) | 2037 (711–6277) | 6565 (2213–11,627) | 1882 (636–11,164) | 1992 (680–11,627) | Not applicable |
Lungshunt (%) | 5 (0.1–17) | 2.3 (1–26) | 4.6 (0.3–16) | 4.5 (0.1–17) | 3.4 (0.8–26) | 4 (0.1–26) |